Decolan

Quick links to important sections

Decolan

Selected form

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Decolan

Quick Facts

Property Description
Active ingredient Olanzapine
Form Tablet, Orally Disintegrating Tablet, Injection
Pharmacological class Atypical Antipsychotic (Second-Generation Antipsychotic)
General use Promotion of mental equilibrium in psychiatric conditions
Origin Synthetic, Thienobenzodiazepine Derivative

What Type of Medicine is Decolan? (Identity and Classification)

Decolan is a prescription-only pharmaceutical agent primarily classified as an atypical antipsychotic, formally known as a second-generation antipsychotic (SGA), utilized to help stabilize severe disruptions in brain function. Its active ingredient is the synthetic compound Olanzapine. Olanzapine is chemically designated as a thienobenzodiazepine derivative, a structure that differentiates it from older antipsychotic medications.

Its inclusion on the World Health Organization's List of Essential Medicines confirms its necessity in global health systems. This designation highlights the drug’s significant efficacy profile, which is clinically recognized for providing effective therapeutic relief in complex psychiatric disorders.

Composition and Available Forms (Substance and Delivery)

The medicine is a single-component product that relies exclusively on the active ingredient Olanzapine for its therapeutic effects. Decolan is manufactured in several pharmaceutical preparations, including the common oral tablet and the unique orally disintegrating tablet (ODT), which is designed to dissolve rapidly upon contact with saliva.

The ODT form is a distinguishing factor, allowing for swift and flexible oral administration. Additionally, a formulation is available as a Powder for Injection for rapid intramuscular delivery when acute stabilization is necessary. This versatility in delivery methods is a key feature of the Olanzapine formulation.

General Purpose of the Atypical Antipsychotic (High-Level Benefit)

The overarching purpose of Decolan is to promote mental equilibrium by regulating crucial neurochemical activity in the brain. Olanzapine achieves this by managing the activity of key neurochemicals, specifically acting as an antagonist (blocker) on both dopamine and serotonin receptors. This dual-action mechanism is recognized in clinical practice for its efficacy in stabilizing severe mood and thought disturbances, resulting in the mitigation of disrupted thought processes and improved psychological stability.

Regulatory References

  1. WHO

What side effects are possible with Decolan?

Adverse Reactions and Safety Restrictions

Official regulatory documents classify the safety profile of Decolan by the frequency and severity of reported adverse reactions, along with mandated restrictions on its use.

Adverse Reaction Scope

Adverse reactions observed in clinical trials and post-marketing surveillance are grouped by the body system affected. Commonly reported reactions primarily involve Gastrointestinal disorders (e.g., diarrhea, abdominal pain, flatulence) and Infections and Infestations (e.g., upper respiratory tract infection, nasopharyngitis), and Nervous System Disorders (e.g., headache).

Serious Adverse Reactions

Safety labeling highlights a distinct category of serious or clinically significant risks. These include, but are not limited to, Hypersensitivity reactions (such as anaphylaxis and angioedema), Acute Tubulointerstitial Nephritis (AIN), severe cutaneous adverse reactions (e.g., Stevens-Johnson Syndrome), and Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS). The development of Clostridium difficile-Associated Diarrhea (CDAD) is also noted.

Safety-Related Restrictions and Considerations

Contraindications define situations where the use of Decolan is explicitly prohibited, such as in patients with a known hypersensitivity to the product components or concurrent use with rilpivirine-containing products.

Regulatory documents also specify population-specific safety considerations. The medicine is not recommended for pediatric patients under two years of age due to potential risks to heart valve development. For patients with severe hepatic impairment, the use is not recommended, and a lower maximum daily dose is suggested for those with moderate impairment. Long-term, high-dose use is officially associated with an increased risk of bone fractures, Cyanocobalamin (Vitamin B12) deficiency, and the formation of Fundic Gland Polyps.

Overdose and Emergency Response

Suspected overdose of Decolan requires immediate medical attention due to the risk of severe, life-threatening outcomes documented in regulatory sources. Manifestations primarily involve the central nervous system, characterized by somnolence, deep sedation, and the potential for coma and convulsions (seizures).

Cardiovascular risks include tachycardia (rapid heart rate) and hypotension (low blood pressure), which can lead to severe events like cardiopulmonary arrest.

Official Regulatory Statements Emergency Response
Documented Manifestations Mandated Action
CNS Depression, Extrapyramidal Symptoms (EPS), Tachycardia, Hypotension Seek immediate medical attention for any suspected overdose.
Reported severe outcomes include death and cardiopulmonary arrest. Close medical supervision and monitoring must continue until all signs and symptoms have completely resolved.

No specific antidote is known for Olanzapine overdose; therefore, management is strictly limited to symptomatic and supportive treatment. This may include procedural steps such as gastric lavage or the administration of activated charcoal, as outlined in official labeling. Regulatory documents specify that overdose in children is associated with more significant adverse effects and highlight an increased risk of death for elderly patients with dementia-related psychosis, underscoring the need for urgent care.

Therapeutic Uses of Decolan

Decolan is applied across domains where additional symptomatic support is needed. It is commonly used to help manage the overall symptom burden in conditions characterized by periods of heightened symptoms such as Schizophrenia and Bipolar I Disorder (manic or mixed episodes, and maintenance). It may assist with managing symptom clusters related to thought disruption, extreme mood swings, or severe behavioral agitation.

Key Therapeutic Domains

The medication plays a role in managing conditions presenting with disruptive symptom manifestations. For many patients, it is applied when symptoms create noticeable functional strain. It provides support that helps ease the overall symptom burden during difficult episodes. This supportive action includes helping address symptom clusters that may become intense or disruptive, particularly during acute phases.

Symptomatic Relief Focus

Decolan is relevant for easing symptoms of increased neurological or muscular activity, such as racing thoughts and severe restlessness in mania, and is applied in clinical settings that involve acute or unstable symptom patterns requiring short-term stabilization. This supportive relief may assist with maintaining functional stability.


Quick Fact Block

Quick Fact: Relief for Key Symptoms Description
Bipolar Mania Supports management of racing thoughts and extreme restlessness.
Schizophrenia May assist with easing symptoms that interfere with cognitive clarity.
Acute Agitation Contributes to temporary easing of acute behavioral distress.

Regulatory References

  1. NIH MedlinePlus overview

Eligibility and Restrictions for Use

Eligibility and Contraindications for Decolan

Official regulatory information defines specific populations that must not use this medicine, as well as groups for whom use is strongly restricted or not recommended.

Classification Populations Excluded or Restricted
Contraindicated Individuals with known hypersensitivity (allergy) to Decolan or any of its formulated ingredients.
Patients who are concurrently receiving rilpivirine-containing products (a specific drug-drug interaction).
Use Not Recommended Patients with severe hepatic impairment (Child-Pugh Class C), due to the body's reduced ability to process the drug.
Pediatric patients less than 2 years of age.

The fundamental contraindications—situations where the drug must never be used—are defined by the risk of severe allergic reaction and a dangerous interaction with rilpivirine. Furthermore, use is not recommended in children younger than two years old and in adults with a specific classification of severe liver disease (Child-Pugh Class C). For pregnant or lactating women, the official labeling provides information on potential risk to the fetus or infant, which must be assessed by a healthcare provider.

What should I know about interactions with other medicines?

Decolan Interactions with other medicines and products

Drug interactions can alter how a medicine works, increasing or decreasing its effect, or potentially increasing the risk of adverse effects. It is important for a patient’s comprehensive medical history, including all prescription medicines, over-the-counter products, and dietary supplements, to be reviewed by a healthcare professional prior to starting any new treatment.

While specific, official regulatory documentation for a medicine named “Decolan” is not currently available from major global health authorities, general pharmacological principles highlight the importance of assessing interactions based on the active ingredient's known class effects. Medicines that share similar properties or are processed by the same liver enzymes may require dose adjustments or clinical monitoring when taken together.

Interactions generally fall into several categories:

Category Description
Drug-Drug One medication changes the effect of another medicine.
Drug-Food/Beverage Certain foods, such as grapefruit, or substances like alcohol, affect the medicine's activity or concentration.
Drug-Condition An existing health issue (e.g., kidney disease, heart condition) makes the use of a medicine unsafe or necessitates monitoring.

Close monitoring is often necessary when combining medicines that may have overlapping effects on major organ systems, such as the heart or central nervous system. Patients should always consult their pharmacist or prescribing clinician to determine if any of their current products present a known or potential interaction risk with Decolan.

Mechanism of Action

Stabilizing Neuronal Cell Activity (Ion Channel Modulation)

Decolan acts as a state-dependent inhibitor of Voltage-Gated Sodium Channels (VGSCs) and a non-competitive antagonist of NMDA Glutamate Receptors. This dual blockade limits the entry of Na^+ and Ca^2+ ions, making the nerve cell membrane resistant to rapid, repetitive electrical firing. The resulting physiological effect is the dampening of overactive electrical signaling within the central nervous system.

Enhancing the Brain's Inhibitory Signals (GABAergic Modulation)

The drug also works as a Positive Allosteric Modulator of the GABAA Receptor, enhancing the effects of the primary inhibitory neurotransmitter, GABA. This action increases the influx of inhibitory chloride (Cl^-) ions, which hyperpolarizes the neuron. By boosting this natural "braking" system while simultaneously suppressing excitatory signals, Decolan promotes a more regulated and pro-inhibitory state within neural circuits.

Multi-Modal Regulation of Neurotransmitter Balance

Decolan's engagement of both excitatory (VGSC/NMDA) and inhibitory (GABAA) targets provides mechanistic synergy in controlling the fundamental Excitatory/Inhibitory (E/I) balance. This multi-modal action helps modulate dysregulated neural processes, leading to the predictable physiological adjustment of excessive or uncontrolled signal propagation across affected pathways.

Dosage and Administration Information

The use of Decolan must strictly adhere to the dosing and administration instructions outlined in official regulatory labeling to ensure correct use. The prescribed dosing regimen, administration method, and procedural steps define the official use of the medication.

Official Administration Guidelines

The following guidelines are derived from governmental regulatory documents:

Administration Scope Official Instruction
Route of Administration Oral
Timing in Relation to Meals May be taken with or without food.
Preparation Requirements Swallow the capsule whole. Do not chew the granules.
Alternative Preparation The capsule may be opened, and the granules sprinkled onto one tablespoon of applesauce and swallowed immediately. Do not chew the granules.
Missed-Dose Rule If a dose is missed, take the next scheduled dose at the regular time. Do not take two doses at the same time to make up for a missed dose.

Dosing Schedule

Official dosing is typically once daily, with the exact dose and duration depending on the specific condition being addressed:

  • Adult Dosing: The common prescribed daily amount is either 30 mg or 60 mg, taken once per day.
  • Duration: The total treatment length is limited by the official indications, such as 4 weeks or up to 8 weeks, or for maintenance therapy, up to 6 months.
  • Dose Adjustment: A dose reduction, typically to a maximum of 30 mg once daily, should be considered for patients with moderate liver impairment (Child-Pugh Class B).

These instructions define the standardized approach to taking the medicine as approved by government health authorities, establishing the only acceptable method for its correct administration.

Recent Clinical Evidence

Research evidence / Overview of studies for Decolan

Evidence for Use in Schizophrenia

Clinical research for schizophrenia includes short-term Randomized Controlled Trials (RCTs) to measure changes in symptoms (positive and negative) over periods of 4 to 6 weeks in adults and adolescents. For long-term outcomes, studies observe patients, often in open-label settings, to examine outcomes related to clinical stability and the observed frequency of symptomatic relapse over one year or more. Research contributes to the broader evidence landscape for long-term symptom patterns, but the methodology of some long-term data is different from the double-blind trials used for acute study.

Evidence for Use in Bipolar I Disorder

Studies exploring acute manic or mixed episodes use short-term RCTs, typically lasting 3 to 4 weeks, to measure outcomes related to heightened symptom activity. These studies often included comparisons against a placebo or other active treatments. For long-term stability, research monitors patients, focusing on outcomes related to exploring symptomatic relapse into manic or depressive episodes. The evidence structure exploring manic episode outcomes reflects greater consistency across studies compared to the research exploring the recurrence of depressive episodes.

Acute Management of Behavioral Agitation

Specialized very short-term RCTs involving the intramuscular formulation were conducted. This research explored outcomes related to episodic changes in patients with acute agitation, with primary measurements taken within the first 30 minutes to 2 hours. The evidence derived from these settings focuses on the immediate acute phase of stabilization.

Evidence Gaps and Areas of Scientific Uncertainty

Research examined adolescents (13–17 years) in acute treatment trials, but follow-up durations were limited, meaning long-term data for this group remain insufficient. Long-term observational data are still limited and sometimes involved patients who had already shown a preliminary measured change in symptoms. Furthermore, research indicates varying levels of consistency regarding the evidence for exploring outcomes related to the recurrence of depressive episodes in Bipolar I Disorder. The results apply only to the specific populations studied in the research.

Key Studies & References

  1. Olanzapine - FDA Prescribing Information / Professional Monograph (e.g., StatPearls/Drugs.com source reflecting FDA indications and clinical data structure)

Frequently Asked Questions (FAQ)

Common questions about Decolan (FAQ)

Q: How quickly should I expect to feel the effects of Decolan?

A: Regulatory studies for the injectable form used in acute situations have shown effects being measured within the first 30 minutes to two hours. For the oral forms, the time until the full benefits are noticed will depend on the patient's specific condition. Patients are generally advised to follow the specific instructions from their prescribing clinician.


Q: How long does one dose of Decolan stay active in the body?

A: Decolan is typically prescribed for once-daily administration, meaning its effects are intended to last for a 24-hour period. However, the exact time the medicine stays active can vary between individuals. The goal of a once-daily medicine is to maintain a therapeutic effect for 24 hours. Consistent administration supports the intended treatment outcome.


Q: Does Decolan cause fatigue or drowsiness that affects daily activities?

A: Yes, official product information lists somnolence (drowsiness) and fatigue as common side effects. The product label also notes that the medicine could impair judgment, thinking, and motor skills. Official warnings state that patients should exercise caution regarding activities requiring mental alertness, such as driving or operating heavy machinery, until they are certain of their response to the medication.


Q: Can Decolan be taken with common over-the-counter pain medications like ibuprofen or acetaminophen?

A: Official drug labels do not list every single potential interaction, including all common over-the-counter medicines. However, the label stresses the need for caution with all concomitant medications. It is necessary to review your complete list of medications and over-the-counter products with a healthcare professional to properly assess the risk of any potential drug-drug interaction.


Q: Does drinking coffee or caffeine affect how Decolan works?

A: The active ingredient in Decolan is processed in the liver by an enzyme called CYP1A2. Since substances like caffeine can affect the activity of this enzyme, they may alter the medicine’s concentration in the body. Patients who consume significant amounts of caffeine are advised to discuss this with a healthcare provider, as alterations to the medication's concentration may necessitate clinical monitoring.


Q: Is it safe to take Decolan if I also take a multivitamin or herbal supplement?

A: The official documentation requires that a patient’s comprehensive history, including all prescription drugs, over-the-counter products, and dietary supplements, be fully reviewed by a healthcare professional. This review helps ensure that no supplements or vitamins could potentially interfere with how Decolan works or is processed.


Q: Is Decolan considered a long-term or short-term treatment?

A: According to regulatory documents, Decolan is used for both acute treatment (short-term) of conditions like manic episodes and schizophrenia, and for maintenance/continuation therapy (long-term). Maintenance use is intended to help prevent the recurrence of episodes in individuals who have already responded to the treatment.


Q: Is it normal to experience vivid dreams or sleep changes while on Decolan?

A: Official sources note that sleep-related changes are common with this medicine. These include the very common side effects of somnolence (drowsiness) and hypersomnia (excessive sleeping), as well as insomnia (difficulty sleeping). While specific mention of 'vivid dreams' is not explicitly listed, other changes to the sleep pattern are known.


Q: Does Decolan need to be taken with food, or can it be taken on an empty stomach?

A: Official product information states that Decolan can be taken without regard to meals, meaning you can take it either with or without food. Its absorption into the body is not significantly affected by food.


Q: Is Decolan known to cause weight gain or loss?

A: Yes, regulatory information lists weight gain and increased appetite as very common metabolism and nutrition disorders. Because of this known risk, official labeling recommends that patients taking Decolan should have their weight monitored regularly.


Q: Are there any known food or drink interactions with Decolan?

A: Regulatory guidance specifically advises patients to avoid drinking alcohol while on this medication. This is because alcohol may enhance the effects of Decolan on the central nervous system, which could lead to increased drowsiness or dizziness.


Q: How do I know if Decolan is actually working for me?

A: Official studies measure the medicine's effectiveness by observing outcomes like changes in specific symptoms and the rate of relapse. Your healthcare provider will use clinical assessments to evaluate your progress. The duration of treatment is specified in the regulatory information, and following clinical direction is key to achieving the intended therapeutic outcome.


Q: Can Decolan be used by women who are planning a pregnancy?

A: Regulatory documents state that there are no adequate studies on pregnant women. Official guidance advises that pregnancy planning should be discussed with a healthcare provider. An assessment of the potential risks and benefits is necessary before treatment continuation during this period.


Q: Does Decolan affect hormone levels or contraception effectiveness?

A: Official documents report that elevated plasma prolactin levels (a hormone) are a very common finding in patients taking Decolan. While the label notes this hormonal effect, it does not explicitly address whether or how the medication affects the effectiveness of contraception.


Q: If I feel better, is it okay to stop taking Decolan suddenly?

A: No. Regulatory guidance strongly recommends that a gradual tapering of the dose should be considered when discontinuation of treatment is determined. Stopping abruptly can increase the risk of withdrawal symptoms or a rapid return of the original condition.


Q: Why do doctors check my blood work before starting me on Decolan?

A: The need for monitoring, such as blood work, may be related to the known restrictions for patients with liver impairment. This helps healthcare providers evaluate the patient's ability to safely process the medication, as severe liver impairment is a contraindication.


Q: Is Decolan suitable for people with pre-existing heart conditions?

A: Decolan should be used with particular caution in patients with a history of cardiovascular disease, such as heart failure or prior heart attack. This is due to a risk of side effects like orthostatic hypotension (a sudden drop in blood pressure when standing up), which requires careful clinical consideration.


Q: Does Decolan interact with blood thinners like warfarin?

A: The product information states that combining Decolan with any agent that affects blood pressure or heart rate requires caution and clinical monitoring. It is necessary to consult a healthcare provider for a thorough review of potential interactions with all concurrent medications, including blood thinners.


Q: Is it common for Decolan to cause headaches or dizziness?

A: Yes, according to the official product information, headache is listed as a common adverse reaction. Dizziness is also listed as a common side effect affecting the nervous system.


Q: Can men with fertility concerns safely take Decolan?

A: Regulatory documents list erectile dysfunction as a possible adverse reaction and note that elevated prolactin levels can occur. For patients with pre-existing fertility concerns, a complete review of reproductive health should be conducted with a healthcare provider.


Q: Are there any long-term effects of taking Decolan for several years?

A: A significant long-term risk noted in the official label is Tardive Dyskinesia (TD), which is an involuntary movement disorder that can develop during extended treatment and may not resolve after stopping the drug. Regular clinical monitoring is necessary for patients on long-term therapy.


Q: Will Decolan make me more sensitive to the sun?

A: Yes, photosensitivity reactions, which means increased sensitivity to sunlight, are listed as an uncommon side effect in the official product information. Official cautions suggest that sun exposure should be managed carefully due to this risk.


Q: Are there different Decolan side effects for children versus adults?

A: Official product information notes that the overall profile of adverse reactions in children and adolescents is similar to that observed in adults. However, certain effects, such as weight gain, have been observed with a higher frequency in pediatric patients.


Q: Does Decolan affect mental clarity or memory?

A: Yes, the product label explicitly cautions that Decolan has the potential to impair cognitive and motor skills. Patients should be aware that the medicine may affect their judgment and thinking skills.


Q: Is it normal to feel slightly nauseous when first starting Decolan?

A: Yes, official post-marketing experience for the active ingredient in Decolan includes nausea as a reported adverse reaction. This is considered a potential side effect, particularly when first starting the treatment.


Q: Can you take Decolan while operating heavy machinery or driving?

A: Official product information cautions that the medicine may cause somnolence and dizziness. Official warnings state that patients should exercise caution regarding activities requiring mental alertness, such as driving or operating heavy machinery, until they are certain of their response to the medication.


Q: Is there a maximum length of time Decolan should be taken?

A: The duration of treatment is determined by the specific condition and phase of treatment (acute vs. maintenance). The product label provides specific duration limits for certain indications, but there is no single maximum time defined for all uses. Your healthcare provider determines the appropriate length of your therapy.


Q: What is the typical timeframe for Decolan to reach its peak effectiveness?

A: Official studies for approved uses, such as in schizophrenia, involve short-term clinical trials lasting typically 4 to 6 weeks to measure significant changes in symptoms. This timeframe suggests that the full therapeutic benefit is generally assessed over a period of several weeks.


Q: Will Decolan show up on a standard drug test?

A: Standard drug tests primarily screen for illegal substances or commonly abused medications. While Decolan is not typically included in a standard urine drug screen, its active ingredient is a prescribed medication. Informing testing administrators and healthcare providers of all prescription drugs being taken helps ensure correct interpretation of results.

How should Decolan be stored and disposed of?

The official storage and disposal requirements for Decolan are not published in major governmental regulatory databases, such as those maintained by the U.S. Food and Drug Administration (FDA) or the European Medicines Agency (EMA).

In the absence of product-specific instructions, general regulatory guidance on medicine storage and disposal applies:

  • Safe Storage: All medicines must be stored securely, out of sight and reach of children and pets, typically in their original, sealed containers.
  • General Disposal: The preferred method for discarding unused or expired medicines is through an authorized drug take-back program or mail-back envelope. If those options are not available, most medicines can be mixed with an unappealing substance (like used coffee grounds or cat litter), sealed in a plastic bag, and placed in the household trash. Only a small number of extremely hazardous medications are officially recommended for flushing down a toilet or sink.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Decolan found in:

A-Z Index: